Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and ...

The final appraisal document for Dupixent (dupilumab) has given the green light ... It is the second indication for the IL-4 and IL-13 inhibitor cleared for use by the NHS in England and Wales ...

three, four IL 17s and that will do well ... story is pretty interesting from our perspective and orthogonal to dupilumab. But also, subsequently we've worked out exactly why former smokers ...

Sanofi/Regeneron's IL-4 and IL-13 inhibitor Dupixent (dupilumab) was approved to treat CRSwNP in 2019, and was joined on the US market by GSK's IL-5 inhibitor Nucala (mepolizumab) last year.

Ebglyss, the third biologic targeting IL-13 for atopic dermatitis, follows Dupixent (dupilumab) and Adbry/Adtralza (tralokinumab) to market. Its less frequent dosing, more selective IL-13 inhibition, ...

EBGLYSS™, the third biologic targeting IL-13 for atopic dermatitis, follows DUPIXENT® (dupilumab) and ADBRY®/ADTRALZA® (tralokinumab) to market. Its less frequent dosing, more selective IL-13 ...